Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Anteris Technologies Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
PP&E Net
AU$7.8m
CAGR 3-Years
48%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
PP&E Net
AU$20.7m
CAGR 3-Years
31%
CAGR 5-Years
25%
CAGR 10-Years
29%
Polynovo Ltd
ASX:PNV
PP&E Net
AU$24.2m
CAGR 3-Years
7%
CAGR 5-Years
32%
CAGR 10-Years
38%
SDI Ltd
ASX:SDI
PP&E Net
AU$45.3m
CAGR 3-Years
29%
CAGR 5-Years
19%
CAGR 10-Years
10%
Ansell Ltd
ASX:ANN
PP&E Net
$435.5m
CAGR 3-Years
7%
CAGR 5-Years
14%
CAGR 10-Years
8%
Next Science Ltd
ASX:NXS
PP&E Net
$1.5m
CAGR 3-Years
14%
CAGR 5-Years
19%
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's PP&E Net?
PP&E Net
7.8m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's PP&E Net amounts to 7.8m AUD.

What is Anteris Technologies Ltd's PP&E Net growth rate?
PP&E Net CAGR 5Y
18%

Over the last year, the PP&E Net growth was 73%. The average annual PP&E Net growth rates for Anteris Technologies Ltd have been 48% over the past three years , 18% over the past five years .

Back to Top